

T: 0131-244 2528
E: annie.gonelli@gov.scot

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Medical Directors NHS Boards

19th September 2024

Dear Healthcare Professional,

**DRUG ALERT CLASS 3 no 42 2024 – MEDICINES RECALL – ACTION WITHIN 5 DAYS -
ORION PHARMA (UK) LTD, ELDEPRYL 5MG TABLETS (SELEGILINE)**

Please see the attached drug alert for onward transmission as below.

Could all Directors of Pharmacy please forward this alert to: -

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors forward this alert to: -

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

ANNIE GONELLI
Medicine Policy Team



Medicines & Healthcare products
Regulatory Agency

M E D I C I N E S R E C A L L

CLASS 3 MEDICINES RECALL

Action Within 5 Days
Pharmacy/Wholesaler Level Recall

Date: 18 September 2024

EL (24)A/42

Our Ref: DMRC-31814730

Dear Healthcare Professional,

Orion Pharma (UK) Ltd

Eldepryl 5mg Tablets

PL 27925/0004

SNOMED Code 669511000001106

Batch No	Expiry Date	Pack Size	First Distributed
2167829	07.2026	100 tablets	22.09.2023

Active Pharmaceutical Ingredient: Selegiline hydrochloride

Brief description of the problem

Orion Pharma (UK) Ltd is recalling the above batch as a precautionary measure due to an out of specification result in the assay result during the follow up stability study of the batch. Only the batch in the table is affected.

Advice for healthcare professionals

Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Advice for patients

No further action is required by patients as this is a Pharmacy and Wholesaler level recall. Patients should continue to take medicines from these batches as prescribed by your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

Further Information

For medical information enquiries please email UK.MedicalInformation@orionpharma.com, or telephone 01635 520300.

For stock control enquiries please email orionukar&customerservices@orionpharma.com.

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully



Medicines & Healthcare products Regulatory Agency

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
DMRC@mhra.gov.uk